Evidence map›Paper›PMID 41871249›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V

Himanshu Batra, Sai Luo, Kevin O Saunders, Jaclyn S Higgins, Fanchong Jian, Jun Zhang, Md Golam Kibria, G M Jonaid, Qingchen J Zhou, Amanda Eaton and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Himanshu Batra *Howard Hughes Medical Institute, Boston Children's Hospital, Boston, MA 02115.
Sai LuoHoward Hughes Medical Institute, Boston Children's Hospital, Boston, MA 02115.
Kevin O Saunders *Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Jaclyn S Higgins *Departments of Epidemiology and Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
Fanchong JianBiomedical Pioneering Innovation Center, Peking University, Beijing 100871, China.ORCID 0000-0001-8703-3507
Jun ZhangDivision of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115.
Md Golam KibriaDivision of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115.
G M JonaidDivision of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115.
Qingchen J ZhouHoward Hughes Medical Institute, Boston Children's Hospital, Boston, MA 02115.
Amanda EatonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Kenneth CroninDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Michael L MalloryDepartments of Epidemiology and Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
Melissa MattocksDepartments of Epidemiology and Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
Robert J EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Esther M LeeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Adam Yongxin YeHoward Hughes Medical Institute, Boston Children's Hospital, Boston, MA 02115.
Aimee Chapdelaine WilliamsHoward Hughes Medical Institute, Boston Children's Hospital, Boston, MA 02115.ORCID 0000-0001-9402-4326
Geeyoun JungHoward Hughes Medical Institute, Boston Children's Hospital, Boston, MA 02115.
Katayoun MansouriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
S Munir AlamDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Ming TianHoward Hughes Medical Institute, Boston Children's Hospital, Boston, MA 02115.
Ralph S BaricDepartments of Epidemiology and Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.ORCID 0000-0001-6827-8701
Yunlong CaoBiomedical Pioneering Innovation Center, Peking University, Beijing 100871, China.ORCID 0000-0001-5918-1078
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710.
Bing ChenDivision of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115.ORCID 0000-0002-8625-1657
Frederick W AltHoward Hughes Medical Institute, Boston Children's Hospital, Boston, MA 02115.

Funding

Molecular Biology of Viral Diseases Predoctoral Training GrantT32AI007419 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark T Heise, CARY A MOODY · 1993 to 2026
$4.7M
Bill and Melinda Gates Foundation (GF) INV-064556Boya Postdoctoral Fellowship Program of Peking University GZC20250980Changping Laboratory (CPL) 2025D0401HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID) AI158571HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID) P01 AI15857Massachusetts Consortium on Pathogen Readiness (MCPR) N/AMinistry of Science and Technology of China 2021D0102National Natural Science Foundation of China 32222030NIAID NIH HHS T32 AI007419
6 · The paper itself

Abstract

During V(D)J recombination, antibody diversity is enhanced by nontemplated junctional modifications that generate immensely diverse heavy chain (HC) and light chain (LC) complementarity-determining 3 antigen-contact regions (CDR3s). We previously developed a mouse model that generates diverse antibody repertoires by rearranging a single human V

Indexed as

Antibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralCOVID-19SARS-CoV-2AnimalsComplementarity Determining RegionsDisease Models, AnimalHumansImmunoglobulin Heavy ChainsMiceSpike Glycoprotein, CoronavirusAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralComplementarity Determining RegionsImmunoglobulin Heavy ChainsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibodiesCDR3 diversityhumanized mouse modelSARS-CoV-2V(D)J recombination

Identifiers

PMID41871249
PMCPMC13037937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.